SP2

Across TCGA pan-cancer cohorts, SP2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SP2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SP2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SP2 is over-expressed in tumor, although a few such as LUAD and CCRCC show the opposite, repressed pattern.

LUAD, CCRCC, and LSCC are the cancer types where SP2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SP2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	−0.221	<.001	8	view →
CCRCC	All	II,III,IV	−0.170	.011	5	view →
LSCC	All	All	−0.100	<.001	4	view →
COAD	Male	All	−0.403	.020	2	view →
PDAC	All	III,IV	−0.278	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SP2–LUAD

Open the LUAD breakdown →